{"entity":{"id":"nct07412613","kind":"trial","name":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","aka":[],"tldr":"A phase 3 trial of Cadonilimab, CAPOX, Capecitabine in colorectal cancer, run by Akeso, now recruiting.","summary":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer is a phase 3 interventional study registered as NCT07412613 by Akeso, with 386 participants planned, started 2026-04-15 and due to reach its primary completion in 2030-06-15. Interventions recorded: Cadonilimab (AK104), Oxaliplatin, Capecitabine, 5- Fluorouracil, Calcium Folinate. Conditions listed: Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07412613","url":"https://clinicaltrials.gov/study/NCT07412613"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal","msi-high-colorectal"],"sections":[],"technologies":["bispecific-antibody","checkpoint-inhibitor"],"targets":[],"drugs":["cadonilimab","capox","capecitabine","leucovorin"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07412613","phase":"3","setting":"A Randomized, Open-label, Controlled, Multicenter Phase 3 Clinical Trial of AK104 for Neoadjuvant/Adjuvant Treatment of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","sponsor":"Akeso","participation":[{"nct":"NCT07412613","source":"https://clinicaltrials.gov/study/NCT07412613","fetchedAt":"2026-10-07T16:55:44.977Z","studySha256":"c09fbb07d664d777feebee91851d87688aca636c5454b879d53b626381e3a8b1","overallStatus":"RECRUITING","lastUpdatePosted":"2026-04-22","leadSponsor":"Akeso","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":386,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-04-15","startedType":"actual","enrolled":386,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07412613/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}